Downgrades by analysts can often lead to a negative short-term reaction in the stock market as they may reflect a less optimistic outlook on the company's future performance. The downgrade from Overweight to Neutral by a reputable analyst could lead to a decrease in investor confidence and a subsequent drop in Aclaris Therapeutics' stock price.